IQV

IQVIA Holdings, Inc.

$265.12

-2.21%
Nov 13, 2026
Bobby Quantitative Model
IQVIA Holdings Inc. is a global provider of clinical research services and healthcare data, technology, and analytics to the life sciences industry, operating through two segments: Research & Development Solutions (outsourced clinical development, spanning trial design, patient recruitment, site management, and regulatory support) and Technology & Analytics Solutions (commercial analytics, real-world evidence, and outsourced sales services). Formed in 2016 from the merger of Quintiles and IMS Health, IQVIA is the clear market leader in clinical research outsourcing (CRO) and the dominant owner of proprietary healthcare data assets, giving it a distinctive 'data plus services' moat that blends the recurring-revenue characteristics of an information provider with the project-based economics of a CRO. The current investor narrative centers on a sharp re-rating: shares have surged roughly 57% over six months as revenue growth reaccelerated to 8% year-over-year in Q3 2026 and margins expanded, with the July 2026 quarter (revenue up ~8.7% YoY) triggering a single-day move of more than 13% that reset the stock's trajectory. Debate now hinges on whether this momentum is durable — bulls point to AI-enabled data monetization and a stabilizing biotech funding backdrop, while skeptics flag a stretched multiple, elevated leverage, and a thin current ratio as reasons for caution after such a powerful run.

People also watch

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc.

TMO

Analysis
Danaher Corporation

Danaher Corporation

DHR

Analysis
Natera

Natera

NTRA

Analysis
IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

IDXX

Analysis
Agilent Technologies

Agilent Technologies

A

Analysis

BobbyInvestment Opinion: Should I buy IQV Today?

Rating: Buy. IQVIA pairs a dominant 'data plus services' franchise with a 17.6% implied upside to the $311.89 average analyst target and a 'strong buy' consensus (18 Buy, 2 Hold, 0 Sell, recommendation mean 1.3), and the core thesis is that a 34% trailing-to-forward PE compression (28.5x to 18.7x) means investors are paying a modest multiple for earnings that are already visibly arriving — Q3 2026 net margin of 7.9% versus 5.9% in Q2 and gross margin of 33.8% versus 32.6% in Q1. The $268.00 low target sitting just 1.1% above the $265.12 current price frames the risk/reward as asymmetric, with the Street's bear case implying near-zero downside.

Supporting evidence is broad: revenue grew 8.0% YoY to $4.428 billion in Q3 2026 with consistent sequential expansion ($4.151B to $4.368B to $4.428B), operating income of $572 million produced a 12.9% operating margin and EBITDA of $952 million a 21.5% EBITDA margin, and TTM free cash flow of $2.079 billion comfortably covers $203 million of quarterly interest while funding buybacks ($552 million in Q1, $398 million in Q2). ROE of 20.9% confirms an asset-light, cash-generative model, and the 2.38x price-to-sales and 18.0x EV/EBITDA are undemanding for a healthcare data franchise. The stock has also outperformed SPY by 54.6 points over six months, evidence the re-rating is idiosyncratic rather than beta-driven.

The biggest risks that could invalidate this thesis are the balance sheet (2.49x debt-to-equity, 0.749 current ratio, roughly 2.8x interest coverage), a 6.34 PEG that leaves no room for an earnings shortfall, and cyclical exposure of the $2.639 billion R&D Solutions segment to biotech funding. This Buy would upgrade to a higher-conviction stance if forward EPS guidance moves above the $19.79 consensus or the current ratio climbs above 1.0, and it would downgrade to Hold if Q4 revenue growth decelerates below 7% or if the forward PE expands beyond roughly 22x without matching EPS revisions. Verdict: fairly valued to modestly undervalued — the 28.5x trailing PE sits in the lower half of a historical band that reached 42.0x in Q4 2022 and 37.7x in Q3 2024, so the 57% six-month rally has been earned by earnings rather than pure multiple expansion.

Sign up to view all

IQV 12-Month Price Forecast

The forward setup favors the bulls: IQVIA trades at 18.7x forward earnings against 28.5x trailing, and the earnings needed to close that gap are already visible in the margin progression from 5.9% in Q2 to 7.9% in Q3 2026. Analyst sentiment is about as strong as it gets — 18 Buys, no Sells, and a low target that sits essentially at the current price — which limits perceived downside but also means expectations are high. The main constraint on conviction is the balance sheet: 2.49x debt-to-equity, a 0.749 current ratio, and roughly 2.8x interest coverage leave little cushion if growth slips, and the 6.34 PEG shows the trailing multiple is not cheap relative to history. I would upgrade to high confidence if Q4 revenue growth holds at or above 8% with forward EPS guidance intact, and I would downgrade to neutral if growth decelerates below 7% or the stock breaks below the $250-$258 support zone.

Historical Price
Current Price $265.12
Average Target $298.50
High Target $346.00
Low Target $230.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on IQVIA Holdings, Inc.'s 12-month outlook, with a consensus price target around $311.89 and implied upside of +17.6% versus the current price.

Average Target

$311.89

20 analysts

Implied Upside

+17.6%

vs. current price

Analyst Count

20

covering this stock

Price Range

$268 - $346

Analyst target range

Buy
18 (90%)
Hold
2 (10%)
Sell
0 (0%)

Coverage is deep and overwhelmingly bullish: 18 analysts rate the stock, with 18 Buy ratings, 2 Hold ratings, and zero Sells, producing a consensus recommendation of 'strong buy' and a recommendation mean of 1.3 (where 1.0 is a strong buy). The average target price of $311.89 implies roughly 17.6% upside from the current $265.12, a meaningful gap that signals the Street sees further appreciation despite the stock's powerful run. The consensus leans firmly bullish, and the recent institutional ratings flow reinforces this — TD Cowen, Truist, Baird, JP Morgan, Evercore ISI, Stifel, Mizuho, Barclays, and RBC all reiterated Buy/Outperform/Overweight ratings in late September and October 2026, with no downgrades in the visible record. The target range runs from a low of $268.00 to a high of $346.00, a spread of about 29% around the average that indicates moderate — not extreme — dispersion in analyst views. The high target of $346.00 (roughly 30.5% above the current price) likely assumes continued margin expansion, accelerating technology-and-analytics growth, and multiple expansion toward the stock's historical PE band; the low target of $268.00 (just 1.1% above the current price) essentially prices in the stock being fairly valued today, implying limited downside even in the bear case. The tightness of the low end to the current price is notable — it suggests analysts see the stock as near fair value with asymmetric upside, and the absence of any Sell ratings or recent downgrades points to strong conviction. Consensus forward EPS of $19.79 and revenue of $22.67 billion underpin these targets, and the alignment between the forward PE of 18.7x and the average target implies the Street is valuing IQVIA on forward earnings at a multiple consistent with its growth profile.

Drowning in data?

Find the real signal!

Bulls vs Bears: IQV Investment Factors

The bull case currently holds stronger evidence: 18 Buy ratings with zero Sells, a 17.6% implied upside to the $311.89 average target, expanding margins (net margin 7.9% in Q3 versus 5.9% in Q2), and $2.079 billion in TTM free cash flow all point to a business executing well while trading at a forward PE of 18.7x that sits in the lower half of its historical band. The bears' strongest cards are balance-sheet-related — 2.49x debt-to-equity, a 0.749 current ratio, and 2.8x interest coverage — plus a 6.34 PEG that demands the forward earnings acceleration actually arrive. The single most important tension is whether the high-single-digit revenue growth (8.0% YoY) can accelerate enough to deliver the $19.79 consensus EPS; if it does, the forward multiple looks cheap and the stock grinds toward $312, but if growth stalls near 8% while leverage stays elevated, the trailing 28.5x multiple looks rich and the re-rating unwinds. Momentum has already decelerated (1.19% over one month versus 56.8% over six months), so the next earnings print is the decisive test of which side wins.

Bullish

  • Analyst consensus overwhelmingly bullish: All 18 covering analysts rate IQV a Buy with zero Sells, producing a 'strong buy' consensus and a 1.3 recommendation mean. The $311.89 average target implies 17.6% upside from $265.12, and the $268.00 low target sits just 1.1% above the current price, signaling analysts see limited downside even in a bear scenario.
  • Forward PE compression signals earnings growth: The stock trades at 28.5x trailing but only 18.7x forward earnings — a 34% compression that implies consensus EPS of $19.79 versus the current run-rate. This frames IQV as reasonably valued if the expected earnings acceleration materializes, and the current multiple sits in the lower half of its historical band (42.0x in Q4 2022, 37.7x in Q3 2024).
  • Margin expansion across 2026 quarters: Q3 2026 net margin rose to 7.9% from 5.9% in Q2 and 6.6% in Q1, while gross margin expanded to 33.8% from 32.9% and 32.6% over the same quarters. EBITDA margin of 21.5% and operating income of $572 million confirm genuine operating leverage, not just revenue growth.
  • Strong free cash flow funds leverage: TTM free cash flow of $2.079 billion (Q3 alone $667 million) comfortably covers the $203 million quarterly interest expense and supports both the 2.49x debt-to-equity load and aggressive buybacks ($552 million in Q1, $398 million in Q2). ROE of 20.9% reflects an asset-light, cash-generative model.

Bearish

  • Elevated leverage and thin liquidity: Debt-to-equity of 2.49x and a current ratio of just 0.749 signal a stretched balance sheet with limited near-term liquidity buffer. Interest expense of $203 million consumes a large share of $572 million operating income, leaving interest coverage near 2.8x — thin for a company simultaneously spending heavily on buybacks.
  • PEG of 6.34 flags rich trailing multiple: A PEG ratio of 6.34 indicates the 28.5x trailing PE is expensive relative to historical growth rates. High-single-digit revenue growth (8.0% YoY in Q3 2026) must accelerate meaningfully toward the $19.79 forward EPS to justify the current price, leaving little room for execution error.
  • Momentum decelerating near 52-week high: The stock is up only 1.19% over the past month and 12.0% over three months versus 56.8% over six months, and it sits at roughly 85% of its 52-week range ($154.50–$284.50). With resistance just 7.3% above at $284.50 and a 2.21% pullback in the latest session, the easy re-rating gains appear largely captured.
  • Cyclical exposure to biotech funding: The Research & Development Solutions segment ($2.639 billion) depends on trial volumes and biotech funding, which is sensitive to capital-market conditions and rate levels. A funding freeze among small biotechs would pressure bookings and slow the high-single-digit growth that underpins the forward earnings story.

IQV Technical Analysis

IQVIA is in a powerful, sustained uptrend: the stock is up 18.6% over the past year and an extraordinary 56.8% over six months, with the current price of $265.12 sitting at roughly 85% of its 52-week range (low $154.50, high $284.50). That positioning near the upper end of the range signals strong momentum but also leaves limited headroom to the prior high, meaning the stock is closer to overextension than to a value entry point. The 6-month gain of 56.8% versus a 1-year gain of 18.6% implies most of the appreciation occurred in the last two quarters, a hallmark of a re-rating rather than a slow grind higher. Short-term momentum remains constructive but has decelerated: the stock is up 1.19% over the past month and 12.0% over three months, a marked slowdown from the explosive six-month pace, and the most recent session saw a 2.21% pullback from the prior close. Notably, IQVIA is outperforming the market on every horizon — relative strength of +3.45 over one month, +14.86 over three months, and +54.63 over six months versus SPY — even as the S&P itself fell 2.26% over the past month, underscoring genuine idiosyncratic strength rather than beta-driven gains. The 1-month/1-year divergence (modest recent gains against a strong annual trend) looks more like healthy consolidation near highs than a reversal, particularly given the stock's 17.6% YTD advance. Key technical levels are well defined: support sits at the 52-week low of $154.50, with nearer-term support likely in the $250–$258 zone where the stock consolidated in August and early November, while resistance is the 52-week high of $284.50, just 7.3% above the current price. A breakout above $284.50 would confirm the uptrend and likely invite momentum buyers, whereas a breakdown below $250 would signal the re-rating has stalled and put the $230s back in play. With a beta of 1.165, IQVIA is roughly 17% more volatile than the market — meaningful for position sizing — and a maximum drawdown of -35.87% over the period is a reminder that this name can correct sharply; the short ratio of 2.21 indicates minimal short-seller pressure, removing a potential squeeze catalyst but also confirming the bullish consensus.

Beta

1.17

1.17x market volatility

Max Drawdown

-35.9%

Largest decline past year

52-Week Range

$155-$285

Price range past year

Annual Return

+18.6%

Cumulative gain past year

PeriodIQV ReturnS&P 500
1m+1.2%-1.2%
3m+12.0%-2.4%
6m+56.8%+2.8%
1y+18.6%+12.3%
ytd+17.6%+10.6%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

IQV Fundamental Analysis

Revenue is growing at a solid, steady clip: Q3 2026 revenue of $4.428 billion rose 8.0% year-over-year from $4.100 billion in Q3 2025, and the sequential progression from $4.151 billion in Q1 to $4.368 billion in Q2 to $4.428 billion in Q3 shows consistent quarter-over-quarter expansion. The multi-quarter trend is one of modest acceleration — Q2 2026 revenue of $4.368 billion was up 8.7% from $4.017 billion a year earlier, and Q1's $4.151 billion was up 8.4% from $3.829 billion — indicating growth has stabilized in the high-single digits after a softer stretch. Segment data shows Technology & Analytics Solutions at $5.336 billion and Research & Development Solutions at $2.639 billion (likely a partial-period or segment-reporting basis), with the technology/data franchise providing the higher-margin, recurring backbone while the R&D services arm supplies cyclical trial-volume exposure. For a company of this scale, high-single-digit growth is respectable and supports the thesis that IQVIA is compounding steadily rather than decelerating. Profitability is robust and improving: Q3 2026 net income of $350 million on $4.428 billion of revenue produced a 7.9% net margin, up from 5.9% in Q2 and 6.6% in Q1, while gross margin of 33.8% expanded from 32.9% in Q2 and 32.6% in Q1. Operating income of $572 million (12.9% operating margin) and EBITDA of $952 million (21.5% EBITDA margin) confirm the company is solidly profitable with expanding operating leverage, and the 13.4% operating margin and 8.3% net margin are consistent with a services-and-data business of this type. The Q4 2025 gross margin of 6.7% is an accounting anomaly (reflecting a reclassification of cost of revenue) and should be disregarded; the underlying trend across 2026 is clearly one of margin expansion. Balance sheet and cash flow present the main blemish: debt-to-equity of 2.49x is elevated, the current ratio of 0.749 signals tight near-term liquidity, and interest expense of $203 million in Q3 consumes a meaningful share of operating income (interest coverage of roughly 2.8x). Still, free cash flow is strong — $2.079 billion TTM, with quarterly FCF of $667 million in Q3, $360 million in Q2, and $491 million in Q1 — and ROE of 20.9% is healthy, indicating the company generates ample cash to service debt and fund growth internally. The company is also returning capital aggressively, repurchasing $552 million of stock in Q1 2026 and $398 million in Q2, which supports EPS but competes with debt reduction for cash; the combination of high leverage, a sub-1.0 current ratio, and buybacks is the key financial risk to monitor.

Quarterly Revenue

$4.4B

2026-09

Revenue YoY Growth

+8.0%

YoY Comparison

Gross Margin

33.8%

Latest Quarter

Free Cash Flow

$2.1B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Research And Development Solutions
Technology And Analytics Solutions

Open an Account, get $2 TSLA now!

Valuation Analysis: Is IQV Overvalued?

Because IQVIA is solidly profitable (Q3 2026 net income of $350 million, positive TTM earnings), the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 28.5x but a forward PE of just 18.7x — a striking 34% compression that implies the market expects earnings to grow substantially, consistent with consensus EPS estimates of $19.79 for the forward period versus the current run-rate. That wide trailing-to-forward gap is the single most important valuation signal here: investors are paying a modest multiple for expected future earnings, which frames the stock as reasonably valued if growth materializes. On peer comparison, IQVIA's 28.5x trailing PE and 18.0x EV/EBITDA sit at a premium to the broader market but are broadly in line with — and arguably modest relative to — high-quality healthcare data and CRO peers, which typically command multiples in the high-teens to low-20s on forward earnings. The 2.38x price-to-sales ratio is low for a data-and-analytics franchise, reflecting the lower-margin services mix, while the 6.34x PEG ratio is elevated and suggests the trailing multiple is rich relative to historical growth — a caution flag that the forward earnings acceleration must actually deliver. The 5.96x price-to-book is high, consistent with an asset-light, high-ROE business model. Historically, IQVIA's PE has ranged widely: it traded at 42.0x in Q4 2022, 39.4x in Q1 2024, and 37.7x in Q3 2024, versus 28.5x today, placing the current multiple in the lower half of its multi-year band. Similarly, the price-to-sales ratio of 2.38x compares favorably to historical readings of 8–12x in 2022–2024 (though methodology differences may affect comparability). The takeaway is that despite the 57% six-month rally, IQVIA is not trading at a historical premium on earnings — the re-rating has been driven by earnings growth catching up to price, which is a healthier setup than pure multiple expansion and suggests the valuation is not yet stretched relative to its own history.

PE

28.5x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 19x~42x

vs. Industry Avg

35.2x

Industry PE ~35.2x*

EV/EBITDA

18.0x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on the balance sheet. Debt-to-equity of 2.49x and a current ratio of 0.749 leave little near-term liquidity cushion, and quarterly interest expense of $203 million against $572 million of operating income implies interest coverage of roughly 2.8x — a thin margin for a company simultaneously repurchasing $552 million and $398 million of stock in Q1 and Q2 2026. Revenue is also concentrated in two segments, with the $2.639 billion R&D Solutions arm exposed to cyclical trial volumes and biotech funding, while the forward valuation depends on EPS climbing to $19.79 from a trailing run-rate that produced a 28.5x PE; any shortfall in that earnings acceleration would leave the multiple exposed. Free cash flow of $2.079 billion TTM is the key mitigant, but it is already committed to buybacks and debt service, limiting flexibility if conditions tighten.

Market and competitive risks are dominated by valuation compression and cyclical sensitivity. At 28.5x trailing earnings and a 6.34 PEG, IQV carries a premium that assumes continued margin expansion and technology-and-analytics growth; a deceleration back toward mid-single digits would likely compress the multiple toward the low end of its historical band. The stock's beta of 1.165 means it is roughly 17% more volatile than the market, so a risk-off rotation or a rise in rates that pressures biotech funding — the lifeblood of the R&D Solutions segment — would hit IQV harder than the index. Competitive pressure from other CROs and data providers, plus any regulatory scrutiny of healthcare data monetization, could erode the 'data plus services' moat that justifies the premium, and the recent deceleration in momentum (1.19% over one month versus 56.8% over six months) suggests the market is already beginning to question how much upside remains.

The worst-case scenario is a growth stall combined with multiple compression: if Q4 2026 revenue growth slips below the 8.0% delivered in Q3 and forward EPS guidance is cut, the stock could retrace toward its 52-week low of $154.50, a decline of roughly 42% from the current $265.12. A more moderate adverse path — a pullback to the $230s consolidation zone or the $250–$258 support area — would represent a 3% to 13% loss, while the historical maximum drawdown of -35.87% shows the stock is capable of sharp corrections after strong runs. Notably, the analyst low target of $268.00 sits above the current price, so the Street's bear case implies only about 1% downside; the real tail risk is a fundamental miss that forces target cuts, which would open the gap toward the $154.50 low and the $230s support.

FAQ

Ranked by severity, the first risk is financial: debt-to-equity of 2.49x, a current ratio of 0.749, and roughly 2.8x interest coverage ($203 million quarterly interest against $572 million operating income) leave little cushion, especially while the company repurchases stock. Second is valuation/earnings risk: a PEG of 6.34 and a 28.5x trailing PE mean the $19.79 forward EPS consensus must be delivered; any shortfall would compress the multiple toward the low end of its historical band. Third is cyclical exposure — the $2.639 billion R&D Solutions segment depends on biotech funding and trial volumes, which are sensitive to rates and capital-market conditions, and a funding freeze would pressure bookings. Fourth is market/technical risk: a beta of 1.165 makes IQV roughly 17% more volatile than the market, and after a 56.8% six-month gain with momentum decelerating to 1.19% over the past month, a mean-reversion move toward the $250-$258 zone or the $230s is a realistic correction, with the historical maximum drawdown of -35.87% showing how sharp these can be.

The three-scenario framework assigns a 55% probability to the base case, a 25% bull case, and a 20% bear case. The base case targets $285-$312 as revenue growth holds at 7-8%, net margin stays in the 7-8% range, and the stock grinds toward the $311.89 average analyst target on forward EPS of $19.79, with the 18.7x forward multiple roughly stable. The bull case targets $312-$346 if Q4 revenue growth holds at or above 8.0% and management guides forward EPS above consensus, allowing a re-rating toward the $346.00 high target. The bear case targets $230-$268 if growth slips below 7%, forward EPS guidance is cut, and biotech funding tightens, with the $268.00 analyst low acting as a first marker rather than a floor. The base case is most likely, and its key assumption is that the margin progression from 5.9% in Q2 to 7.9% in Q3 2026 proves durable rather than a one-quarter anomaly.

The answer depends heavily on which multiple you anchor to. On trailing earnings the stock looks full at 28.5x with a PEG of 6.34, which flags the trailing multiple as rich relative to historical growth. But on forward earnings it trades at just 18.7x — a 34% compression that implies consensus EPS of $19.79 is achievable — and that forward multiple sits in the lower half of a historical band that reached 42.0x in Q4 2022 and 37.7x in Q3 2024. The 2.38x price-to-sales and 18.0x EV/EBITDA are undemanding for a healthcare data franchise, while the 5.96x price-to-book reflects an asset-light, 20.9% ROE model. The market is therefore paying a fair-to-modestly-undervalued price on forward earnings, but it is implicitly assuming the earnings acceleration actually materializes. Verdict: fairly valued to modestly undervalued relative to its own history, with the caveat that the trailing multiple leaves no room for an earnings shortfall.

From a risk/reward standpoint the setup is favorable but not without caveats. The stock trades at $265.12 against a $311.89 average analyst target, implying 17.6% upside, and the $268.00 low target sits just 1.1% above the current price — meaning the Street's bear case prices in essentially zero downside. The forward PE of 18.7x versus 28.5x trailing means investors are paying a modest multiple for earnings that consensus expects to arrive ($19.79 forward EPS), and 18 Buy ratings with zero Sells reinforce the conviction. The biggest downside risk is a growth stall that forces target cuts and opens the gap toward the $230s or the $154.50 52-week low, compounded by 2.49x debt-to-equity and a 0.749 current ratio. It is a good buy for investors with a 12-24 month horizon who can tolerate a beta of 1.165 and a leveraged balance sheet in exchange for a cash-generative healthcare data franchise; it is less suited to those needing income (0% dividend) or near-term certainty after a 56.8% six-month run.

IQV is better suited to a medium-to-long-term hold than to short-term trading. The business is a mature, high-single-digit grower (8.0% revenue growth in Q3 2026) with recurring data revenue, 20.9% ROE, and $2.079 billion in TTM free cash flow — characteristics that reward patience rather than tactical positioning. It pays no dividend (0% yield, 0% payout ratio), so total return depends entirely on earnings growth and multiple support, which argues for a holding period long enough to let the $19.79 forward EPS consensus materialize. The beta of 1.165 and a maximum drawdown of -35.87% mean short-term holders face meaningful volatility, and the recent deceleration (1.19% over one month versus 56.8% over six months) suggests near-term consolidation near the $284.50 high. A suggested minimum holding period is 12-24 months, long enough to capture at least two earnings cycles and to see whether the balance sheet (2.49x debt-to-equity, 0.749 current ratio) improves alongside the margin story.